Ziresovir Offers New Hope for Treating Respiratory Syncytial Virus Infections

Respiratory syncytial virus (RSV) causes respiratory tract infections in children and adults. While for many patients the outcomes of infection are mild, for others, infection can prove fatal, and there is a lack of effective treatments. Dr Jim Wu from the Shanghai Ark Biopharmaceutical Company in China carries out his vital research to develop new, safe, and effective treatments to tackle this killer.